Mercados españoles abiertos en 39 mins

CareDx, Inc (CDNA)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
8,28+0,43 (+5,48%)
Al cierre: 04:00PM EDT
8,28 0,00 (0,00%)
Después del cierre: 04:20PM EDT

CareDx, Inc

8000 Marina Boulevard
Brisbane
South San Francisco, CA 94005
United States
415 287 2300
https://caredx.com

Sector(es)Healthcare
SectorDiagnostics & Research
Empleados a tiempo completo635

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Abhishek JainCFO & Principal Accounting Officer425,58kN/A1977
Dr. Peter Maag Ph.D.Executive Director43,23kN/A1967
Mr. Alexander L. JohnsonPresident of Patient & Testing Services547,43kN/A1974
Ms. Marica Grskovic Ph.D.Chief Operating OfficerN/AN/AN/A
Dr. Robert N. Woodward Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. GS JhaSenior VP, Chief Information Officer & Chief Information Security OfficerN/AN/AN/A
Jeffrey A. NovackGeneral CounselN/AN/AN/A
Ms. Stacey FollonSenior VP & Head of Human ResourcesN/AN/AN/A
Mr. Kashif RathoreChief of Patient & Digital SolutionsN/AN/AN/A
Mr. Hal GibsonSenior Vice President of Strategic PlanningN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Gobierno corporativo

El ISS Governance QualityScore de CareDx, Inc, a día 1 de abril de 2024, es 6. Las puntuaciones base son Auditoría: 10; Tablero: 4; Derechos de los accionistas: 5; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.